PRESS-NEWS.org - Press Release Distribution
PRESS RELEASES DISTRIBUTION

Children’s Hospital of Philadelphia researchers observe significant reduction in diagnosis of food allergies following expert guidelines encouraging early peanut exposure

Diagnosis of anaphylactic food allergy decreased after landmark LEAP study and expert guidelines encouraging early peanut introduction

2025-10-20
(Press-News.org) Philadelphia, October 20, 2025 – Peanuts represent one of the most common causes of immunoglobulin E (IgE)-mediated, or anaphylactic, food allergies in children, yet a landmark study found that early introduction of peanut to infants may lower their risk of developing this allergy. Now, a new study from researchers from Children’s Hospital of Philadelphia (CHOP) has shown that the rates of diagnosis of peanut and other IgE-mediated food allergies have declined since the adoption of guidelines encouraging early introduction practices.

The findings, published today in the journal Pediatrics, highlight how landmark research has been translated into a successful public health campaign.

IgE-mediated food allergies affect about 4% of children, causing a child’s immune system to react abnormally when exposed to one or more foods, such as milk, egg, wheat, peanut, or other nuts. Reactions are immediate, causing symptoms that may include hives, swelling, difficulty breathing and vomiting.

Researchers and clinicians have speculated that IgE-mediated food allergies can be prevented through early-life exposure of food antigens in the gut. A landmark study supportive of this paradigm was the 2015 Learning Early About Peanut Allergy (LEAP) trial, which demonstrated that early exposure of peanut in 4-11 month old infants with severe eczema or egg allergy reduced peanut allergy risk by 81%. Subsequent studies have shown that this protective effect is sustained beyond early childhood.

The findings of the LEAP trial prompted major pediatric and allergy and immunology organizations to develop consensus guidelines to put these findings into practice. Released in 2015 and 2017, these guidelines initially focused on children thought to be at high risk of food allergy. In 2021, new guidelines support introduction of peanut, egg and other major food allergens at 4-6 months in all children without a history of prior reaction.

“Everyone has been wondering whether these landmark public health interventions have had an impact on reducing rates of IgE-mediated food allergies in the United States,” said the study’s first author Stanislaw Gabryszewski, MD, PhD, an attending physician in the Division of Allergy and Immunology and a core faculty member in the Clinical Futures Center of Emphasis at CHOP. “We now have data that suggest that the effect of this landmark public health intervention is occurring.”

Using electronic health record data from the multi-state, primary care-based American Academy of Pediatrics Comparative Effectiveness Research through Collaborative Electronic Reporting (CER2) network, the researchers compared rates of food allergy diagnosis at different time periods, prior to the establishment of early introduction guidelines as well as post-guidelines and post-addendum guidelines.

The study found significant reductions in the prevalence of peanut IgE-mediated food allergy (from 0.79% to 0.45% of the study population) and any IgE-mediated food allergy (1.46% to 0.93% of the population) from the time before the guidelines to after the addendum guidelines were introduced. Peanut transitioned from the topmost to second most common food allergen post-guidelines, surpassed by egg. The authors estimate that for about every 200 infants exposed to food allergens early in life, one child would have been prevented from developing food allergy.

While the early introduction strategy does not completely eliminate peanut and other IgE-mediated food allergies, the reduction in food allergy diagnosis rates is a promising finding that underscores ongoing public health efforts to disseminate early introduction practices.

“Our findings have relevance from those of us who treat patients to those caring for infants, and more awareness, education and advocacy could further increase the positive results we observed in this study,” said senior study author David Hill, MD, PhD, an attending physician with the Division of Allergy and Immunology. “Future studies could potentially explore specific feeding practices that help us better understand the timing, frequency and dose of foods that optimize protection against food allergies.”

This study was supported by the National Institutes of Health grants T32HD043021, K08AI182477 and R01HL162715, the Hartwell Foundation, the American Academy of Allergy Asthma and Immunology, the American Partnership for Eosinophilic Disorders, and the Children’s Hospital of Philadelphia Research Institute. Additional infrastructure funding was provided by the American Academy of Pediatrics and the Health Resources and Services Administration (HRSA) of the U.S. Department of Health and Human Services (HHS) under UA6MC15585 - National Research Network to Improve Children’s Health and U5DMC39344 - Pediatric Research Network Program.

This study was also funded by Food Allergy Fund, an organization aimed at funding research focused on the underlying causes of food allergies and improved treatments for millions of people living with food allergies.

Gabryszewski et al, “Guidelines for Early Food Introduction and Patterns of Food Allergy.” Am Pediatrics. Online October 20, 2025. DOI: 10.1542/peds.2024-070516.

About Children’s Hospital of Philadelphia:  

A non-profit, charitable organization, Children’s Hospital of Philadelphia was founded in 1855 as the nation’s first pediatric hospital. Through its long-standing commitment to providing exceptional patient care, training new generations of pediatric healthcare professionals, and pioneering major research initiatives, the hospital has fostered many discoveries that have benefited children worldwide. Its pediatric research program is among the largest in the country. The institution has a well-established history of providing advanced pediatric care close to home through its CHOP Care Network, which includes more than 50 primary care practices, specialty care and surgical centers, urgent care centers, and community hospital alliances throughout Pennsylvania and New Jersey. CHOP also operates the Middleman Family Pavilion and its dedicated pediatric emergency department in King of Prussia, the Behavioral Health and Crisis Center (including a 24/7 Crisis Response Center) and the Center for Advanced Behavioral Healthcare, a mental health outpatient facility. Its unique family-centered care and public service programs have brought Children’s Hospital of Philadelphia recognition as a leading advocate for children and adolescents. For more information, visit https://www.chop.edu.

END


ELSE PRESS RELEASES FROM THIS DATE:

ESMO 2025: VT3989 continues to show promising early results in patients with advanced mesothelioma

2025-10-19
VT3989 is a first-in-class YAP-TEAD inhibitor from Vivace Therapeutics that is currently in Phase I/II trials for patients with advanced solid tumors, with a focus on refractory mesothelioma In this trial, VT3989 demonstrated notable antitumor activity, with a disease control rate of 86% at the clinically optimized dosing levels These data provide the first clinical proof-of-concept for effectively drugging the Hippo-YAP-TEAD pathway VT3989 was awarded Orphan Drug Designation and Fast Track Designation for the treatment of mesothelioma by the FDA BERLIN, OCTOBER 19, 2025 ― The first-in-class YAP-TEAD inhibitor ...

Study finds COVID-19 mRNA vaccine sparks immune response to fight cancer

2025-10-19
Patients with advanced lung or skin cancer who received a COVID-19 mRNA vaccine within 100 days of starting immunotherapy drugs lived significantly longer than those who did not get the vaccine, researchers have found. The observation by researchers at the University of Florida and the University of Texas MD Anderson Cancer Center is a defining moment in a decade-plus of research testing mRNA-based therapeutics designed to “wake up” the immune system against cancer. Building on a previous UF study, the observation also marks a significant step toward a long-awaited universal cancer vaccine to ...

ESMO 2025: mRNA-based COVID vaccines generate improved responses to immunotherapy

2025-10-19
Cancer patients who received mRNA COVID vaccines within 100 days of starting immunotherapy were twice as likely to be alive three years after treatment as those who never received a vaccine These findings have prompted a randomized Phase III trial to determine if mRNA COVID vaccines should be part of the standard of care for this type of therapy If validated, findings could significantly increase the number of patients who benefit from immunotherapy BERLIN, OCTOBER 19, 2025 ― Patients with cancer who received mRNA-based COVID vaccines within 100 days of starting immune checkpoint therapy were twice as likely to be alive three years after beginning ...

Drug combo cuts risk of death in advanced prostate cancer by 40%

2025-10-19
Men whose prostate cancer returns after surgery or radiation therapy may now benefit from a new drug combination shown in clinical trials to cut the risk of death by more than 40%. The combination therapy, which adds a drug called enzalutamide to commonly prescribed hormone therapy, reduced deaths in patients with recurrent prostate cancer after surgery or radiation for whom other treatments are no longer an option. The trial results were published in The New England Journal of Medicine (NEJM) with simultaneous presentation during the European Society for Medical Oncology Congress (ESMO) Oct. 19 in Berlin. “After ...

ADC improves outcomes for patients with advanced triple-negative breast cancer who are ineligible for immune checkpoint inhibitors

2025-10-19
BERLIN October 19, 2025 – Patients with an aggressive form of breast cancer who are not candidates for immune checkpoint inhibitor therapy showed significantly improved progression-free survival when treated with the antibody drug conjugate sacituzumab govitecan compared to standard chemotherapy. These findings, which stem from the ASCENT-03 trial in triple-negative breast cancer co-led by investigators at Dana-Farber Cancer Institute, are presented today at the European Society for Medical Oncology (ESMO) Congress 2025 in Berlin, Germany. They are also published simultaneously in the New England Journal ...

Novel treatment combination improves progression-free survival in metastatic, estrogen-receptor-positive HER-2-negative breast cancer

2025-10-18
BERLIN October 18, 2025 – Patients with estrogen-receptor-positive HER-2-negative advanced breast cancer showed significantly improved progression-free survival when treated with an oral combination regimen that includes giredestrant, a novel, next-generation selective estrogen receptor degrader and full antagonist, compared to a standard combination approach. These findings, from the phase 3 evERA Breast Cancer study, are presented today by Dr. Erica Mayer of Dana-Farber Cancer Institute at the annual meeting of the European Society for Medical Oncology (ESMO) in Berlin, Germany. Tumors that express the estrogen receptor (ER) account for roughly 70% ...

ESMO 2025: Trial results show belzutifan shrinks rare neuroendocrine tumors and improves symptoms in patients

2025-10-18
Pheochromocytoma and paraganglioma (PPGL) are rare, hard-to-treat neuroendocrine tumors that form in the adrenal glands or in the extra-adrenal paraganglia Study found belzutifan shrank tumors and improved symptoms without surgery Belzutifan is the first oral and only FDA-approved treatment for patients with advanced, inoperable, or metastatic PPGL FDA granted approval for treating PPGL in May 2025 based on these trial results BERLIN, OCTOBER 18, 2025 – A multicenter Phase II clinical ...

ESMO 2025: Dual targeted therapy shows promise in previously treated advanced kidney cancer patients

2025-10-18
Study found patients treated with combination of lenvatinib and everolimus lived longer without disease progression First head-to-head study comparing second-line treatments lenvatinib plus everolimus vs. cabozantinib Combination offers option for patients with metastatic clear-cell renal carcinoma (ccRCC) who experience disease progression following first-line immunotherapy BERLIN, OCTOBER 18, 2025 ― Results from a trial led by researchers from The University of Texas MD Anderson Cancer Center showed that a targeted therapy combination improved outcomes for patients with metastatic clear-cell renal carcinoma (ccRCC) – a type of kidney ...

New generation of Antibody-Drug Conjugates (ADCs) shows unprecedented promise in early-stage disease

2025-10-18
Lugano/Berlin 18 October 2025 - In a landmark moment at the ESMO Congress 2025, pivotal studies have unveiled compelling evidence that a new class of anti-cancer agents—antibody-drug conjugates (ADCs)—can dramatically improve outcomes for patients with early-stage HER2-positive breast cancer.   The results from the phase III DESTINY-Breast05 and DESTINY-Breast11 trials, presented in a Presidential Symposium, mark a paradigm shift in breast cancer treatment, positioning ADCs not only as powerful therapeutic agents when the disease has already progressed but also as potential new standards of care in patients with early disease (1,2).    “There is ...

Sylvester Cancer Tip Sheet for October 2025

2025-10-17
OCTOBER 2025 TIP SHEET (October is Breast Cancer Awareness Month) Breast Cancer Living Near Toxic Sites Linked to Aggressive Breast Cancer Women living near federally designated Superfund sites are more likely to develop aggressive breast cancer – including the hard-to-treat triple-negative subtype – according to new research from Sylvester. Three recent Sylvester studies have uncovered links between breast cancer, Superfund sites and social adversity. Superfund sites are locations contaminated by hazardous waste and identified by the Environmental Protection Agency as needing cleanup to minimize risks to human health and the environment. Sylvester ...

LAST 30 PRESS RELEASES:

Immunotherapy after surgery shows promise in treating rare, aggressive skin cancer

Immunotherapy after surgery shows potential in preventing the spread of aggressive skin cancer

What is the extent of disparities in cancer clinical trials among low- and middle-income countries?

Invisible poison: Airborne mercury from gold mining is contaminating African food crops, new study warns

Nearly half of Finns with chronic conditions find medication therapy a burden

Do animals fall for optical illusions? What fish and birds can teach us about perception

New guideline emphasizes conversations about mood, mental health between patients and clinicians

Children’s Hospital of Philadelphia researchers observe significant reduction in diagnosis of food allergies following expert guidelines encouraging early peanut exposure

ESMO 2025: VT3989 continues to show promising early results in patients with advanced mesothelioma

Study finds COVID-19 mRNA vaccine sparks immune response to fight cancer

ESMO 2025: mRNA-based COVID vaccines generate improved responses to immunotherapy

Drug combo cuts risk of death in advanced prostate cancer by 40%

ADC improves outcomes for patients with advanced triple-negative breast cancer who are ineligible for immune checkpoint inhibitors

Novel treatment combination improves progression-free survival in metastatic, estrogen-receptor-positive HER-2-negative breast cancer

ESMO 2025: Trial results show belzutifan shrinks rare neuroendocrine tumors and improves symptoms in patients

ESMO 2025: Dual targeted therapy shows promise in previously treated advanced kidney cancer patients

New generation of Antibody-Drug Conjugates (ADCs) shows unprecedented promise in early-stage disease

Sylvester Cancer Tip Sheet for October 2025

Three science and technology leaders elected to Hertz Foundation Board of Directors

Jump Trading CSO Kevin Bowers elected to Hertz Foundation Board of Directors

Former Inscripta CEO Sri Kosaraju elected to Hertz Foundation Board of Directors

Citadel’s Jordan Chetty elected to Hertz Foundation Board of Directors

McGill research flags Montreal snow dump, inactive landfills as major methane polluters

A lightweight and rapid bidirectional search algorithm

Eighty-five years of big tree history available in one place for the first time

MIT invents human brain model with six major cell types to enable personalized disease research, drug discovery

Health and economic air quality co-benefits of stringent climate policies

How immune cells deliver their deadly cargo

How the brain becomes a better listener: How focus enhances sound processing

Processed fats found in margarines unlikely to affect heart health

[Press-News.org] Children’s Hospital of Philadelphia researchers observe significant reduction in diagnosis of food allergies following expert guidelines encouraging early peanut exposure
Diagnosis of anaphylactic food allergy decreased after landmark LEAP study and expert guidelines encouraging early peanut introduction